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OBJECTIVE The purpose of this study was to evaluate the safety of
MRI without positioning restrictions in patients with an MR-
conditional pacemaker and currently a non–MR-conditional Med-
tronic CapSureFix Novus 5076 lead(s).
METHODS The study randomized 266 patients in a 2:1 ratio to
the MRI group (177 patients) or to the control group (89
patients). At 9–12 weeks postimplant, the MRI group underwent
MRI at 1.5 T. Primary end points were MRI-related complication-
free rate and noninferiority of the MRI group compared to the
control group with regard to the proportion of patients with an
increase ofr0.5 V in right atrial (RA) and right ventricular (RV)
pacing capture thresholds from immediately before MRI to
1-month after MRI.
RESULTS No MRI-related complications occurred in 156 MRI-
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1547-5271 B 2015 Heart Rhythm Society. Open access under CC BY-NC-ND licenseDifferences in the proportion of patients with r0.5 V pacing
capture threshold changes from pre-MRI to 1-month post-MRI were
minimal between the groups for RA (proportions of 100% in both
groups; a P value cannot be calculated) and RV leads (proportions
of 99.3% in the MRI group and 100% in the control group;
noninferiority test, P o .0001). Proportions of patients with
acceptable sensing amplitude changes from pre-MRI to 1-month
post-MRI were also similar between the 2 groups for RA and RV
leads (noninferiority test, Po .0001 and P ¼ .0004, respectively).
No arrhythmias occurred during MRI.
CONCLUSION MRI scans can be performed safely without position-
ing restrictions in patients with Medtronic CapSureFix Novus 5076
leads connected to an MR-conditional pacemaker.ABBREVIATIONS CIED ¼ cardiac implantable electronic device;
MR ¼ magnetic resonance; MRI ¼ magnetic resonance imaging;
PCT ¼ pacing capture threshold; RF ¼ radiofrequency
(Heart Rhythm 2015;12:759–765) I 2015 Heart Rhythm Society.
Open access under CC BY-NC-ND license.Introduction
Magnetic resonance imaging (MRI) is one of the most
widely used noninvasive imaging modalities because of its
unparalleled soft tissue contrast and negligible side effects
even on repeated scans. It is estimated that 50%–75% of
patients with pacemakers or other cardiac implantable
electronic devices (CIEDs) may need to undergo MRI over
their lifetime for noncardiac or cardiac indications,1 with
many patients requiring repeated examinations.2 MRI is
relatively contraindicated in non–magnetic resonance (MR)-
conditional pacemakers because of potential adverse inter-
actions between pacemakers and MRI.3 The potentiallyhttp://dx.doi.org/10.1016/j.hrthm.2014.12.035.
Heart Rhythm, Vol 12, No 4, April 2015760hazardous effects of MRI on CIEDs can be caused by the
static magnetic, switched gradient magnetic, and pulsed
radiofrequency (RF) ﬁelds and are modulated by patient-
speciﬁc characteristics such as lead position, patient posi-
tioning, and lead design.4 With regard to lead design,
material, geometry, and insulation of the lead among other
factors also inﬂuence the effect of MRI on the pacemaker
system.
The introduction of MR-conditional pacemakers has
enabled more patients to undergo routine MRI assessment
without risk of morbidity or device malfunction. Several
manufacturers have released leads and devices designed and
labeled for use in the MRI environment (designated MR-
conditional devices). However, an important limitation exists
in patients with existing non–MR-conditional pacemaker
systems that could beneﬁt from receiving an MR-conditional
pacemaker. Lead extraction is rarely performed, especially
during a pulse generator replacement; therefore, retained
non–MR-conditional leads would render the entire pace-
maker system non-MR conditional. However, if the preex-
isting lead were MR conditional with the pulse generator
being non-MR conditional, replacement with an MR-
conditional pulse generator would make the whole system
MR conditional and would be advantageous.
Many MR-conditional pacemaker systems are also lim-
ited by anatomical scan zone and positioning restrictions.
These restrictions, imposed by regulative authorities based
on device as well as clinical trial design, differ between
manufacturers.5 These restriction scans limit the ability to
perform MRI scans in the thoracic region6 but have been
removed from the Advisa MRI pacemaker system (Med-
tronic, Inc, Minneapolis, MN) through clinical evaluation.7
Since its release in the year 2000, more than 1 million
CapSureFix Novus 5076 (5076) leads have been implanted,
but with no MR-conditional labeling because of lack of data
on the clinical safety of MRI scans with these leads. If
proved safe, it would permit replacement of only the existing
pulse generators to MR-conditional pulse generators—with-
out lead replacement—and allow access to conditional MRI
for patients with 5076 leads. This would be beneﬁcial not
only to patients but also to the health care system, as lead
replacement has higher complication rates and ﬁnancialEnrollment
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Figure 1 Study visit ﬂowchart. F/U ¼ followimplications than does the replacement of pulse generators
alone.8Methods
This was a prospective, randomized, controlled, nonblinded,
multicenter study involving 36 sites located in Europe, India,
Southeast Asia, China, Saudi Arabia, South Africa, Australia,
and South America. The Declaration of Helsinki was followed,
as well as laws and regulations of participating countries.
Institutional review board approval and patient informed
consents were obtained. Patients included in the study were
those who had class I or II dual-chamber pacemaker indications
and pectoral implants.9 Patients were included in the study if
they agreed to undergo protocol-required nonindicated MRI
scan without sedation, had no implanted non–MR-conditional
devices or materials, had no other implantable-active medical
devices, and had no abandoned leads.
Sample size calculations called for 270 patients to be
enrolled. Patients who were enrolled underwent implantation
of a complete 5076 MRI study system, consisting of 2 new
5076 (atrial and ventricular) leads and an Advisa MRI pulse
generator, or if the patient had previously implanted 5076
leads, they received only an Advisa MRI pulse generator. All
patients enrolled were randomized after successful implant
was completed, either on the day of implant or before
hospital discharge (Figure 1). Patients were randomized in
a 2:1 ratio to the MRI group or the control group stratiﬁed by
center and using randomized blocks. After randomization, all
patients were followed in the ofﬁce at 8 and 9–12 weeks
postimplant. Patients in the MRI group received a series of
MRI scans of the chest and head. Patients in the control
group were required to come in for a 9–12-week visit and did
not undergo an MRI scan but had an approximately 1-hour
waiting period. During these visits, immediately before and
after MRI or waiting period, a complete device interrogation
was performed and all parameters including the right atrial
and right ventricular pacing capture thresholds (PCTs) at a
pulse width of 0.5 ms, sensing amplitudes, and lead
impedances were collected. Additional follow-up was per-
formed 1-week post-MRI (or waiting period) and 1-month
post-MRI (or waiting period).Control Group
Week Waiting Period
One-Week
Post-MRI/Waiting Period
Follow-up
One-Month
Post-MRI/Waiting Period
Follow-up
p Visit
-up; MRI ¼ magnetic resonance imaging.
761Shenthar et al MRI in Patients With CapSureFix Novus 5076 LeadsIn this study, the primary safety objective was to demon-
strate that theMRI-related complication-free rate was490%,
and primary effectiveness objectives were to demonstrate the
noninferiority of the MRI group compared to the control
group with regard to the proportion of patients with an
increase of r0.5 V in atrial and ventricular voltage thresh-
olds at 1-month post-MRI compared with pre-MRI measure-
ments. The secondary end points were (1) to demonstrate the
noninferiority of the MRI group compared to the control
group with regard to the proportion of patients with r50%
decrease in sensing amplitude in the atrial and ventricular
leads at 1-month post-MRI compared with pre-MRI measure-
ments, (2) to characterize change in lead impedance from pre-
MRI to 1-month post-MRI, and (3) to demonstrate that the
freedom of occurrence of sustained ventricular arrhythmias
and asystole during MRI scans was490%.
The MRI scan protocol was modeled after the Advisa
MRI safety and effectiveness trial using 1.5-T cylindrical
MRI systems7 (Table 1). MRI scans were nonindicated, and
sequences were chosen to represent clinically relevant scans
that were similar between scanners. The MRI scans included
14 individual sequences: 11 in the chest and thoracic region
and 3 in the head. In addition, 1 chest sequence was
performed optionally in a substudy, results of which were
inconclusive. The scan protocol included MR scans with
maximized RF energy deposition up to speciﬁc absorption
rate levels of 2 W/kg body and scans with maximized
gradient slew rates. The body coil served as the RF trans-
mitter and coil, and static magnetic ﬁeld exposure was
approximately 60 minutes with cumulative actual MRI scan
times of approximately 30 minutes (gradient and RF ﬁeld
exposure). During MRI scans, monitoring of vital signs was
performed using verbal communication and at least 1
hemodynamic monitoring system: pulse oximeter, electro-
cardiograph, or noninvasive blood pressure measurements.Statistical analysis
For the primary safety objective, a 1-sided, 1-proportion
binomial exact test was used, and the corresponding 1-sided
97.5% lower conﬁdence bound was calculated. For theTable 1 Manufacturers and models of MRI scanners
MRI manufacturer/model
MRI group (N ¼ 159),
n (%)
Siemens Avanto 63 (39.6)
Siemens Aera 29 (18.2)
GE Signa 24 (15.1)
Philips Ingenia 8 (5.0)
Philips Intera 7 (4.4)
Siemens Symphony 7 (4.4)
Siemens Sonata 6 (3.8)
GE Signa HD 5 (3.1)
GE Inﬁnity 3 (1.9)
Philips Achieva 3 (1.9)
Siemens Sonata 3 (1.9)
Siemens unknown 1 (0.6)
MRI ¼ magnetic resonance imaging.primary effectiveness objectives, a 1-sided Farrington-Man-
ning noninferiority test of 2 independent proportions with a
noninferiority margin of 10% was performed. Atrial and
ventricular end points were each evaluated at a signiﬁcance
level of .025. Data imputation methodology was prespeciﬁed
in the protocol. If a PCT measurement immediately before
MRI or control waiting period was unavailable or invalid, a
valid 2-month PCT value was used. If the 1-month post-
MRI/control visit PCT did not exist or was not valid, the 1-
week post-MRI/control visit PCT was used. To assess the
robustness of the analysis of missing/excluded data, a tipping
point analysis10 was performed on the basis of all random-
ized patients separately for atrial and ventricular end points.
The same imputation and testing methods were used for the
sensing amplitude as secondary objective, with a noninfer-
iority margin of 10%.Results
The distribution of 270 patient enrollments, randomization
groups, and primary end point compliance is presented in
Figure 2. Patients were enrolled between March and October
2013 and were followed for a maximum of 4 months, with
the ﬁnal study follow-up occurring in February 2014.
Patient’s characteristics of the randomized patients are
summarized in Table 2.
Of 159 patients who underwent an MRI scan, 156 were
followed through 1-month post-MRI and were included in
the primary safety objective analysis. There were no MRI-
related complications in the 156 patients included in the
analysis (or the 3 not included through known follow-up)
(100% success rate; 1-sided lower 97.5% conﬁdence bound
97.7%). The primary safety objective was met (Po .0001).
While there were no MRI-related complications, the adverse
event advisory committee classiﬁed 1 event as an MRI
procedure–related observation. In this case, the patient
reported skin heating on the back of the hand from a pulse
oximeter during the MRI scan. A superﬁcial skin defect was
noted, and the pulse oximeter was removed.
No patient had an increase of40.5 V in atrial PCT from
pre-MRI/waiting period to 1-month post-MRI, which was
100% success rate (142 of 142) in the MRI group and 100%
(80 of 80) in the control group (Figure 3). With both success
rates at 100%, a noninferiority P value could not be
calculated. There was no increase of40.5 V in ventricular
PCT from pre-MRI/waiting period to 1-month post-MRI in
99.3% (152 of 153) of the MRI group and 100% (82 of 82)
of the control group (Figure 4). The 95% conﬁdence
interval for the difference was 5.4% to 4.1%. For
ventricular PCT, the P value of the Farrington-Manning
test evaluating whether the MRI group was noninferior to
the control group with a 10% margin was o.0001. In the
MRI group, ventricular PCT of 1 patient increased by 1.5 V
from pre-MRI to 1-month post-MRI. Before MRI, this
patient’s ventricular PCT was 0.5 V at implant and 8.0 V at
2 months, which resulted in lead explant and replacement.
After lead replacement, the patient’s ventricular PCT was
Figure 2 CONSORT diagram: PCT analysis population. MRI ¼ magnetic resonance imaging; PCT ¼ pacing capture threshold.
Heart Rhythm, Vol 12, No 4, April 20157621.5 V immediately before MRI, 1.25 V immediately after
MRI, 2.0 V 1-week after MRI, and 3.0 V 1-month after MRI.
It was unlikely that the PCT changes were related to MRI, as
those changes typically occur immediately after MRI, and this
patient had a propensity for higher thresholds. A number of
randomized patients (atrial PCT: 35 [20%] MRI and 9 [10%]
control patients; ventricular PCT: 24 [14%] MRI and 7 [8%]
control patients) did not contribute data to the analysis for
various reasons, including MRI scans not being performed
(eg, missed visit and patient refusal) and atrial arrhythmia
(Figure 2). Tipping point analyses were performed to assess
the potential effects of the missing data. Those analyses
showed that unless the missing patients showed results fardifferent from the observed results (ie., a success rate of 74%
[26 of 35] or less for atrial PCT, and 67% [16 of 24] or less for
ventricular PCT in the MRI group patients with missing data),
the noninferiority tests would still be statistically signiﬁcant.
The atrial sensing amplitude did not decrease by 450%
from pre-MRI to 1-month post-MRI in 97.9% (141 of 144)
of the MRI group as compared with 96.3% (78 of 81) in the
control group. This passed the prespeciﬁed noninferiority
test with Po .0001. Similarly, ventricular sensing amplitude
did not decrease by 450% from pre-MRI to 1-month post-
MRI in 96.4% (134 of 139) in the MRI group as compared
with 96.2% (76 of 79) in the control group (noninferiority
test, P ¼ .0004).
Table 2 Baseline demographic and clinical characteristics
Characteristic MRI group (n ¼ 177) Control group (n ¼ 89)
Age (y) 70.0  10.4 67.8  15.1
Sex: male 109 (62) 49 (55)
Race
White or Caucasian 87 (49) 45 (51)
Asian 52 (29) 26 (29)
Hispanic or Latino 12 (7) 4 (4)
Not available or not provided 26 (15) 14 (16)
Primary indication for implant
Unknown cause/idiopathic induced AV block 77 (44) 39 (44)
Sinus node dysfunction—sinus bradycardia 29 (16) 11 (12)
Sinus node dysfunction—sinus arrest/pause/exit block 15 (8) 11 (12)
Sinus node dysfunction – bradycardia-tachycardia syndrome 14 (8) 9 (10)
Others 42 (24) 19 (21)
Had previously implanted 5076 leads 2 (1) 2 (2)
Atrial arrhythmias 44 (25) 28 (31)
Ventricular arrhythmias* 13 (7) 10 (11)
AV junctional arrhythmias and blocks 118 (67) 68 (76)
Cardiovascular surgery history
Ablation 5 (3) 4 (4)
Coronary artery bypass graft 12 (7) 7 (8)
Coronary artery intervention 21 (12) 5 (6)
Valve surgery 6 (3) 4 (4)
Cardiovascular history
Cardiomyopathy 29 (16) 9 (10)
Myocardial infarction 12 (7) 3 (3)
Syncope 71 (40) 31 (35)
Values are presented as mean  SD or as n (%).
AV ¼ atrioventricular; MRI ¼ magnetic resonance imaging.
*Ventricular arrhythmia includes long QT syndrome, premature ventricular complexes, nonsustained ventricular tachycardia, ventricular ectopic beat, bigeminy,
ventricular extrasystole polymorphic, and cyclic adenosine monophosphate–mediated right ventricular outﬂow tract ventricular tachyacardia.
763Shenthar et al MRI in Patients With CapSureFix Novus 5076 LeadsIn the 159 MRI scans performed, no (0%) ventricular
arrhythmias or asystole events were noted. Changes in the
atrial lead impedance were minimal from pre-MRI/waiting
period to 1-month post-MRI, with the average change being
10.7 35.1 Ω for the MRI group (n ¼ 147) vs 4.2 36.3
Ω for the control group (n ¼ 77), which was not clinically
signiﬁcant. Similarly, change in the ventricular lead impe-
dance was minimal, with the average change being 1.0 
36.1Ω in the MRI group (n¼ 148) and8.4 39.0Ω in the
control group (n ¼ 77), which was again not clinically
signiﬁcant.1%
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Figure 3 Atrial pacing capture threshold changes from the pre-9–12-
week visit to the 1-month post-MRI/control visit. MRI ¼ magnetic
resonance imaging.In the 2 patients with existing 5076 leads who underwent
MRI scans, no adverse events related to study components,
device, or lead deﬁciencies were noted during the study.
There were no deaths during the study.
Discussion
This prospective, randomized, multicenter trial was con-
ducted to evaluate the safety and efﬁcacy of the Medtronic
CapSureFix Novus 5076 lead connected to an Advisa MRI
pulse generator in the MRI environment. More than 1 million
5076 leads have been implanted since 2000, and perform-
ance of the lead has been demonstrated through chronic
evaluation in Medtronic’s product surveillance registry. The0% 1% 5%
75%
16%
2% 1%1% 1%
12%
65%
20%
1% 0%
0%
20%
40%
60%
80%
-0.75 -0.5 -0.25 0 0.25 0.5 1.5
Pe
rc
en
t o
f P
at
ie
nt
s
Change in Ventricular Pacing Capture Threshold (V)
MRI (n=153)
Control (n=82)
Figure 4 Ventricular pacing capture threshold changes from the pre 9-12
week visit to the one-month post-MRI/control visit.
Heart Rhythm, Vol 12, No 4, April 2015764overall 5076 lead survival rate at 11 years is 97.7%.10 In spite
of the broad utilization and demonstrated product perform-
ance, there had been no clinical data to support safety of
exposure to MRI at 1.5 T and hence the 5076 lead has not
been labeled for MR-conditional use. In this study, there
were no MRI-related adverse cardiac events even when MRI
was performed with no positioning restrictions. Similarly, the
electrical performance of the 5076 lead was not affected for
patients who underwent MRI scans at 1.5 T.
The complexity of electromagnetic ﬁelds interacting with
the implanted pacemaker system has made demonstration of
adequate safety and efﬁcacy by either preclinical or clinical
testing imperative. There are 3 distinct sources of Electro-
magnetic Interference in the setting of MRI: the static magnetic
ﬁeld, RF ﬁelds, and time-varying gradient magnetic ﬁelds. The
static magnetic ﬁeld can exert force and torque on CIEDs and
may change the reed switch state in non–MR-conditional
devices, causing unpredictable pacing behaviors.11 The RF and
gradient magnetic ﬁelds may induce electric currents in leads
within the ﬁeld if the current loop is completed through the
body. In addition, the generator and leads can act as an antenna
that ampliﬁes local RF energy deposition, resulting in
heating at the device-tissue interface. Finally, Electromagnetic
Interference may result in the inhibition of pacing, asynchro-
nous pacing, power-on-reset events, inappropriate tracking,
and runaway pacing with induction of potentially life-
threatening ventricular arrhythmias including ventricular ﬁbril-
lation resulting in death.12,13 Patients dependent on pace-
makers are most vulnerable to the effects of power on reset
because the event may result in asystole.14 The Advisa MRI
pulse generator system has system modiﬁcations and program-
ming modalities that allow patients dependent on pacemakers
to undergo safe and reliable MRI scans and has been approved
as an MR-conditional system for clinical use.7
A successful approach to overcome the complexity
employs rigorous preclinical analysis and electromagnetic
modeling and testing. When required, the preclinical work
can be followed by a conﬁrmatory clinical study. Validated
lead electrode heating models provide comprehensive safety
evaluation of thousands of scenarios not attainable with a
clinical trial and allow the evaluation of safety margin by
simulation of key variable values beyond the range of
standard clinical practice, as demonstrated by Wilkoff
et al.15 Computer modeling and in vivo animal testing
predicted that the standard non–MR-conditional 5076 pace-
maker lead can be scanned with an extremely low probability
of PCT changes under the normal operating mode.16
The lead design of the 5076 lead is similar to that of the 5086
lead that has been previously tested and is considered MR
conditional. The 5076 lead has a 4 ﬁlar design instead of a 2 ﬁlar
design and has a smaller lead diameter than does the 5086 lead.
The 5086 lead has been shown to have acceptable lead
performance parameters, but it has been noted to exhibit lower
ventricular sensing, slightly higher ventricular capture thresh-
olds, and higher acute lead dislodgements compared with the
well-established 5076 lead.17 Clinical evaluation has shown that
the 5076 lead has better sensing parameters not only at implantbut also at long-term follow-up than does the 5086 MRI lead.
This has been attributed to platinized helix of the 5076 lead
having modestly higher polarizing characteristics than that of
the slightly stiffer and heavier 5086 lead, causing a small effect
at the lead tip to tissue interphase.17 Since the 5076 lead does not
contain a radiopaque marker unlike the 5086 MRI lead, review
of medical records is indicated for lead identiﬁcation.
With regard to performance in the MRI environment,
Gimbel et al7 proved the CapSureFix 5086 MRI lead and
Advisa MRI pulse generator system to be safe and effective
in the 1.5-T MRI environment without positioning restric-
tions or limitations of body parts scanned. In the present
study, there were no signiﬁcant changes in atrial and
ventricular PCTs and no signiﬁcant decrease in the sensing
amplitude between the MRI and control groups up to 1-
month post-MRI. There was no clinically relevant change in
the impedance of either the atrial or the ventricular lead in the
present study. Likewise, there was no power on reset,
unintended cardiac stimulation, and no arrhythmias includ-
ing asystole noted during MRI in the present study.
During MRI of the chest and thoracic spine, the isocenter
is, respectively, near or within the region of the pacemaker
system, and this may increase the risk of MRI-related adverse
effects on implanted pacemakers. Therefore, the chest/thoracic
region is often excluded even in MR-conditional devices,
many of which do not permit scans whereby the isocenter
landmark falls between the superior surface of the C1 vertebra
and the inferior surface of the T12 vertebra.
Although many of the adverse effects reported during off-
label MRI are infrequent, this may not allay the concerns for
performing regular scans on patients with pacemakers. The
suggestion that off-label MRI is “safe” for patients with
pacemakers remains a cause of concern since fewer than
2000 patients with pacing systems have reportedly undergone
MRI.18 In addition, small sample size, different pulse gen-
erators and lead pairings, and different scan protocols with
positioning restrictions make it difﬁcult to compare while
evaluating the safety of off-label scanning of any speciﬁc
device and lead system.18 Hence, off-label scanning of patients
dependent on pacemakers is strongly discouraged.19,20
In all instances of patients implanted with an MR-
conditional lead, it is a prerequisite that the device has been
in situ for at least 6 weeks before assessment is undertaken to
allow endothelialization of the leads and minimize any
effects of the static magnetic ﬁeld on torque.5 While there
were only 2 patients in the study with existing 5076 leads and
replacement Advisa MRI implantable pulse generators, there
are no differences between new and existing 5076 leads and
these conﬁrmatory data indicate that it is safe to scan patients
with preexisting 5076 leads, provided the pulse generator has
been changed to an MR-conditional one.Study limitations
Since only a single type of pacing system with two 5076
leads and Advisa MRI pulse generator was evaluated, the
results cannot be generalized to other pacing systems. There
765Shenthar et al MRI in Patients With CapSureFix Novus 5076 Leadswere no patients with single-chamber pacemakers, and only
dual-chamber pacemaker systems were evaluated. The study
was conducted using 1.5-T MRI scanners, and the results
cannot be extrapolated to 3 T or lower ﬁeld strengths. There
were very few patients with preexisting 5076 leads who were
enrolled in the trial after only a pulse generator replacement.Conclusion
This study demonstrates that patients implanted with 5076
leads safely undergo MRI scans with an MR-conditional
pulse generator. In such patients, MRI scans can be
performed safely with no positioning restrictions using 1.5-
T MRI scanners, such as direct imaging of the thoracic
region including the spine and the cardiovascular system.Acknowledgments
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2878–2891.CLINICAL PERSPECTIVES
Medtronic CapSureFix Novus 5076 lead(s) had been in use for nearly 14 years with well-established clinical reliability,
however without magnetic resonance imaging (MRI)-conditional labeling. The study establishes the clinical safety of the
5076 lead in the MRI environment without positioning restrictions if used with a magnetic resonance (MR)–conditional
pulse generator. Since the lead not only has shown long-term reliability but has now been proven to be MR conditional
without positioning restriction, it can be used and may replace the 5086 leads in clinical practice. Also, in patients with
preexisting 5076 leads needing a pulse generator replacement with an MR-conditional pulse generator would make MRI
scans possible in these patients.
